NEW YORK (GenomeWeb News) — The New York Genome Center launched its "Innovation Center" today, which will provide its founding members with access to new sequencing technologies.
The NYGC has allocated an undisclosed amount of capital and operational budgets to the Innovation Center to purchase new sequencing platforms for testing by its founding members. The "lab-within-a-lab" is expected to minimize cost and risk for the NYGC participants, while creating "a vibrant community of users that will help shape future sequencing technologies and applications."
The Innovation Center will initially be equipped with four Ion Proton sequencers from Life Technologies, which will be housed at Memorial Sloan-Kettering Cancer Center. The center will receive the platform, which promises to sequence a human genome in a few hours for under $1,000, under early access prior to its commercial release.
The NYGC's pilot laboratory at Rockefeller University is expected to house some of the Innovation Center's sequencing and data analysis until the NYGC moves into its permanent location in Lower Manhattan next year.
Data from the validation of the Ion Proton technology will be shared among the NYGC's founding members.
"The NYGC Innovation Center is serving as a broker of relationships to bring new technologies forward, of which Life Technologies’ Ion Proton sequencer is the first,” Nancy Kelley, founding executive director of the NYGC, said in a statement.
Scientists led by Scott Lowe in the cancer biology and genetics program at the Sloan-Kettering Institute plan to use the new instruments to study mutations in difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma. The technology is expected to enable them to examine genetic changes more quickly than previously possible.